MedPath

Ibandronate

Generic Name
Ibandronate
Brand Names
Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
Drug Type
Small Molecule
Chemical Formula
C9H23NO7P2
CAS Number
114084-78-5
Unique Ingredient Identifier
UMD7G2653W
Background

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.

Ibandronate was granted FDA approval on 16 May 2003.

Indication

For the treatment and prevention of osteoporosis in postmenopausal women.

Associated Conditions
Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
Clinical Trials
Related News

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment

Phase 4
Completed
Conditions
Post-Menopausal Osteoporosis
Interventions
First Posted Date
2007-10-30
Last Posted Date
2011-07-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
781
Registration Number
NCT00551174

A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.

Phase 4
Completed
Conditions
Postmenopausal Osteoporosis
Interventions
Drug: Placebo
First Posted Date
2007-10-17
Last Posted Date
2016-05-12
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
140
Registration Number
NCT00545051

SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.

Phase 4
Completed
Conditions
Post Menopausal Osteoporosis
Interventions
First Posted Date
2007-10-17
Last Posted Date
2015-08-18
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
596
Registration Number
NCT00545480

A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)

Phase 4
Completed
Conditions
Postmenopausal Osteoporosis
Interventions
First Posted Date
2007-10-17
Last Posted Date
2016-10-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
716
Registration Number
NCT00545363

BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis

Phase 4
Completed
Conditions
Postmenopausal Osteoporosis
Interventions
First Posted Date
2007-10-17
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
585
Registration Number
NCT00545909

A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.

Phase 3
Completed
Conditions
Post-Menopausal Osteopenia
Interventions
Drug: Placebo
First Posted Date
2007-10-17
Last Posted Date
2017-01-26
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
150
Registration Number
NCT00545207

BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.

Phase 3
Completed
Conditions
Post-Menopausal Osteoporosis
Interventions
First Posted Date
2007-10-17
Last Posted Date
2016-10-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
677
Registration Number
NCT00545779

ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Phase 4
Completed
Conditions
Post Menopausal Osteoporosis
Interventions
First Posted Date
2007-10-17
Last Posted Date
2016-11-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
561
Registration Number
NCT00545090

Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial

Phase 3
Completed
Conditions
Osteonecrosis of the Knee
Bone Marrow Edema of the Knee
Interventions
Drug: Placebo
First Posted Date
2007-09-20
Last Posted Date
2015-08-26
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
30
Registration Number
NCT00532220
Locations
🇨🇭

University Hospital, Basel, Switzerland

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

Phase 4
Completed
Conditions
Post-Menopausal Osteoporosis
Interventions
First Posted Date
2007-07-18
Last Posted Date
2011-06-17
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
801
Registration Number
NCT00503113
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy